Avadel Pharmaceuticals plc (AVDL) — Financial statements
Income statement, balance sheet, and cash flow for Avadel Pharmaceuticals plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 169↑504.8% | 28 | 0.00 | 0.00↓100.0% | 22 | |
| Cost of Revenue | 15↑1705.8% | 0.85 | 0.00 | 0.00↓100.0% | 6 | |
| Gross Profit | 154↑467.3% | 27 | 0.00 | 0.00↓100.0% | 17 | |
| Operating Expenses | ||||||
| R&D Expenses | 15↑14.6% | 13↓35.9% | 21↑21.0% | 17↓16.3% | 20 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 181↑19.3% | 152↑103.6% | 75↑8.8% | 68↑111.4% | 32 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 3↑6411.3% | -0.05↑99.9% | -42 | |
| Operating Expenses | 196↑19.0% | 165↑67.4% | 99↑15.2% | 86↑693.8% | 11 | |
| Total Costs & Expenses | 212↑27.6% | 166↑68.2% | 99↑15.2% | 86↑417.9% | 17 | |
| Operating Results | ||||||
| Operating Income | -42↑69.2% | -138↓39.9% | -99↓15.2% | -86↓1571.1% | 6 | |
| Depreciation & Amortization | 3↑51.8% | 2↑18.3% | 1↑83.2% | 0.82↓51.8% | 2 | |
| EBITDA | -36↑76.1% | -149↓52.8% | -98↓18.5% | -82↓958.0% | 10 | |
| EBIT | -38↑74.7% | -151↓52.3% | -99↓19.1% | -83↓1151.6% | 8 | |
| Interest & Other Income | ||||||
| Net Interest Income | -11↓9.5% | -10↑19.9% | -12↓24.1% | -10↑23.5% | -13 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 11↑9.5% | 10↓19.9% | 12↑24.1% | 10↓23.5% | 13 | |
| Non-Operating Income | -4↓131.8% | 13↑2333.2% | 0.54↑122.9% | -2↓11.7% | -2 | |
| Other Income / Expenses | -7↑70.9% | -23↓78.0% | -13↓69.5% | -8↑30.3% | -11 | |
| Income Before Tax | -49↑69.5% | -161↓44.3% | -111↓19.6% | -93↓1732.8% | -5 | |
| Income Tax Expense | -0.25↑50.7% | -0.50↓101.9% | 26↑264.5% | -16↓30.6% | -12 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -49↑69.5% | -160↓16.6% | -137↓77.8% | -77↓1200.3% | 7 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -49↑69.5% | -160↓16.6% | -137↓77.8% | -77↓1200.3% | 7 | |
| Bottom-Line Net Income | -49↑69.5% | -160↓16.6% | -137↓77.8% | -77↓1200.3% | 7 | |
| EPS (Basic) | -0.51↑74.5% | -2.00↑12.7% | -2.29↓73.5% | -1.32↓1115.4% | 0.13 | |
| EPS (Diluted) | -0.51↑74.5% | -2.00↑12.7% | -2.29↓73.5% | -1.32↓1115.4% | 0.13 | |
| Weighted Average Shares | 95↑18.7% | 80↑33.4% | 60↑2.7% | 59↑10.5% | 53 | |
| Weighted Average Diluted Shares | 95↑18.7% | 80↑33.4% | 60↑2.7% | 59↑6.5% | 55 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.